| POUR, Luděk, Hana ŠVÁCHOVÁ, Zdeněk ADAM, Martina ALMASI, Dana KRÁLOVÁ, Tomáš BÜCHLER, Lucie KOVÁŘOVÁ, Marta KREJČÍ, Jaroslav MICHÁLEK, Miroslav PENKA, Jiří VORLÍČEK a Roman HÁJEK. Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration. European Journal of Haematology. 2010, roč. 84, č. 4, s. 332-336. ISSN 0902-4441. Dostupné z: https://dx.doi.org/10.1111/j.1600-0609.2009.01396.x. |
Další formáty:
BibTeX
LaTeX
RIS
@article{944233,
author = {Pour, Luděk and Šváchová, Hana and Adam, Zdeněk and Almasi, Martina and Králová, Dana and Büchler, Tomáš and Kovářová, Lucie and Krejčí, Marta and Michálek, Jaroslav and Penka, Miroslav and Vorlíček, Jiří and Hájek, Roman},
article_number = {4},
doi = {http://dx.doi.org/10.1111/j.1600-0609.2009.01396.x},
keywords = {angiogenesis; chemokines; bortezomib; multiple myeloma; therapeutic response},
language = {eng},
issn = {0902-4441},
journal = {European Journal of Haematology},
title = {Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration},
url = {http://onlinelibrary.wiley.com/doi/10.1111/j.1600-0609.2009.01396.x/pdf},
volume = {84},
year = {2010}
}
TY - JOUR
ID - 944233
AU - Pour, Luděk - Šváchová, Hana - Adam, Zdeněk - Almasi, Martina - Králová, Dana - Büchler, Tomáš - Kovářová, Lucie - Krejčí, Marta - Michálek, Jaroslav - Penka, Miroslav - Vorlíček, Jiří - Hájek, Roman
PY - 2010
TI - Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration
JF - European Journal of Haematology
VL - 84
IS - 4
SP - 332-336
EP - 332-336
SN - 09024441
KW - angiogenesis
KW - chemokines
KW - bortezomib
KW - multiple myeloma
KW - therapeutic response
UR - http://onlinelibrary.wiley.com/doi/10.1111/j.1600-0609.2009.01396.x/pdf
N2 - Multiple myeloma (MM) is associated with increased rate of bone marrow angiogenesis. Increased concentration of hepatocyte growth factor (HGF) is associated with poor prognosis in patients treated with conventional chemotherapy or thalidomide. We have shown previously that decreased level of thrombospondin, an angiogenesis inhibitor, correlates with poor response to high-dose chemotherapy. The aim of our current study was to evaluate association between therapeutic response to bortezomib and thrombospondin and HGF levels. Peripheral blood plasma concentration of HGF and bone marrow plasma concentration of thrombospondin were measured in patients with MM prior to the initiation of bortezomib therapy. Overall, 58 patients were enrolled, 44/58 (76%) of them with relapsed disease. Treatment outcomes were analyzed for possible associations with pretreatment HGF and thrombospondin levels. Patients who achieved complete response had significantly higher pretreatment HGF levels and lower pretreatment thrombospondin levels than others. More than 70% of patients with low pretreatment HGF and high pretreatment thrombospondin concentrations achieved very good partial response or complete response, in contrast to only 20% of patients with high HGF and low thrombospondin levels. High pretreatment thrombospondin and low pretreatment HGF concentrations are associated with therapeutic response to bortezomib in patients with MM.
ER -
POUR, Luděk, Hana ŠVÁCHOVÁ, Zdeněk ADAM, Martina ALMASI, Dana KRÁLOVÁ, Tomáš BÜCHLER, Lucie KOVÁŘOVÁ, Marta KREJČÍ, Jaroslav MICHÁLEK, Miroslav PENKA, Jiří VORLÍČEK a Roman HÁJEK. Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration. \textit{European Journal of Haematology}. 2010, roč.~84, č.~4, s.~332-336. ISSN~0902-4441. Dostupné z: https://dx.doi.org/10.1111/j.1600-0609.2009.01396.x.
|
